Sapanisertib

INN name:	Sapanisertib
Lab codes:	MLN0128, HY13328, INK128, TAK228
Chemical name:	3-(2-amino-1,3-benzoxazol-5-yl)-1-(propan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
Molecular formula:	C15H15N7O
Chemical Structure:
CAS Registry Number:	1224844-38-5
Originator:	Intellikine
Developer:	Dana-Farber Cancer Institute; Millennium; National Cancer Institute (USA); Takeda
Class:	Antineoplastic
Mechanism of Action:	MTORC1, MTORC2 protein inhibitors
WHO ATC code:	L01X-E
EPhMRA code:	L1H
Clinical Trials:
Conditions Phases Interventions Status Anaplastic Thyroid Cancer|Thyroid Cancer Phase 2 Alone Recruiting Metastatic Castration-Resistant Prostate Cancer Phase 2 Alone Recruiting Recurrent Adult Acute Lymphoblastic Leukemia Phase 2 Alone Not yet recruiting Stage IV or Recurrent Lung Cancer Phase 2 Alone Not yet recruiting Breast Cancer Phase 1|Phase 2 Combination Recruiting Merkel Cell Carcinoma Phase 1|Phase 2 Alone Not yet recruiting Recurrent Glioblastoma or Advanced Solid Tumors Phase 1 Combination Recruiting Adult Solid Neoplasm Phase 1 Combination Recruiting Advanced Nonhematologic Malignancies Phase 1 Combination Recruiting Advanced Nonhematologic Malignancies Phase 1 Combination Recruiting Advanced Solid Malignancies Phase 1 Alone Active, not recruiting Advanced Solid Malignancies|Hematologic Malignancies Phase 1 Combination Completed Advanced Solid Tumors Phase 1 Alone Recruiting Non-Hematologic Malignancy Phase 1 Combination Recruiting Advanced EGFR Mutation Positive Non-small Cell Lung Cancer Phase 1 Combination Not yet recruiting Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia Phase 1 Alone Completed Recurrent Glioblastoma Alone Recruiting
Recent activities on the drug: